Microbot Medical Inc. 8-K

What Happened
Microbot Medical Inc. (MBOT) filed an 8-K on April 10, 2026 reporting that it has an existing At-the-Market Offering Agreement (Sales Agreement) with H.C. Wainwright & Co., LLC. Under the Company’s ATM Program, the Company may sell common stock having an aggregate offering price of up to $39,230,691. The Sales Agreement dates to June 10, 2021 and was amended July 1, 2024; sales, if any, may be made on Nasdaq or by other methods allowed under Rule 415. The company will file a prospectus supplement to its shelf registration statement on Form S-3 in connection with any offer and sale, and the legal opinion of counsel is included as Exhibit 5.1 to the 8-K.

Key Details

• Aggregate ATM capacity: $39,230,691 of common stock available for sale.
• Sales agent: H.C. Wainwright & Co., LLC (Sales Agreement dated June 10, 2021; amended July 1, 2024).
• Sales methods: at-the-market transactions on Nasdaq, to/through market makers, direct sales to Wainwright as principal, or other lawful methods under Rule 415.
• Regulatory steps: prospectus supplement to Form S-3 will be filed; counsel opinion filed as Exhibit 5.1.

Why It Matters
An ATM program gives Microbot flexibility to raise capital over time by selling shares into the market as needed. If shares are sold, this can increase the company’s cash resources but will dilute existing shareholders’ ownership and could affect the stock price depending on sale size and timing. There were no sales reported in this 8-K — investors should watch for the prospectus supplement and any future filings that disclose actual ATM sales and the number of shares issued.